San Diego-primarily based Viking Therapeutics marked alone as a serious competitor in the weight loss drug sector in February right after revealing promising details from a mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided being a weekly injection and in March the compa